The unit I lead brings together complex models of trauma, haemorrhage, shock, coagulopathy, spinal cord and brain injury to facilitate the full translation of experimental work into the clinics, ensuring animal welfare while providing a unique source of expertise and capability for trauma science.

I am also a Member of the Royal College of Veterinary Surgeons, London (MRCVS).

Research interests:

• To bring together expertise on cutting edge experimental physiology, advanced interventional modelling and technologies such as bioengineering and imaging, to optimise and standardise trauma experimental models.
• To develop an efficacious experimental model pathway to support the development of novel therapeutic.
• To establish complex models integrating neurotrauma, haemorrhage, coagulopathy and organ dysfunction, while working at the interface of collaborative multidisciplinary research groups.

Current projects

• Testing several therapeutic approached to improve the acute clinical management of acute traumatic coagulopathy in a fixed-pressure rodent model of traumatic hemorrhagic shock.
• To development of a model incorporating trauma induced coagulopathy and uncontrolled haemorrhage to enable measurement of a translatable clinical endpoint.
• Implementation of minimally invasive imaging technologies to validate and develop new safety and efficacy readouts for our preclinical trauma models (neuroinflammation, cardiovascular function and tissue perfusion).
• Refinement of welfare assessment and pain management for interventional trauma models.

Other interests

With an MSc in Bioethics , I am very interested in regulatory and ethical aspects related to health and biotechnology issues, with a particular interest in animal welfare, to promote high standards for in vivo research. I am member of the LASA UK and involved in welfare animal research bodies.

Having extensively worked in preclinical imaging, we are very interested in the implementation of forefront imaging modalities in our models, to maximise their translational efficacy and to support the development of new clinical minimally invasive assessment methods and pioneer new biomarkers and biological sensors.